Clearmind Medicine's investigational compound CMND-100 is producing encouraging early signals in an ongoing Phase I/IIa first-in-human clinical trial targeting alcohol use disorder (AUD), with principal investigators publicly highlighting positive initial experience from the study cohort.
CMND-100 is built on MEAI (5-methoxy-2-aminoindane), a non-hallucinogenic psychoactive compound that Clearmind positions as a differentiated approach to AUD pharmacotherapy. Unlike classical psychedelics under investigation for substance use disorders — such as psilocybin or MDMA — MEAI is designed to engage relevant neurological pathways without producing the perceptual distortions that complicate clinical administration and regulatory review. That distinction is increasingly relevant as the psychedelic-derived ingredient space faces intensifying scrutiny from the FDA and scheduling authorities.
Trial Design and Signals
The trial is a Phase I/IIa structure, meaning the study is simultaneously evaluating safety, tolerability, and preliminary efficacy signals in human subjects — a compressed but common design for novel CNS-active compounds seeking early proof-of-concept data. Principal investigators have characterized their real-world observations from the trial as promising, though peer-reviewed endpoint data have not yet been published. For operators and formulators tracking the emerging psychoactive-compound pipeline, the interim read-out represents a meaningful early milestone for a non-hallucinogenic mechanism in a high-burden therapeutic category.
AUD affects an estimated 400 million people globally and represents one of the most underpenetrated indications in both pharmaceutical and nutraceutical development. Current standard-of-care pharmacotherapies — naltrexone, acamprosate, disulfiram — carry significant adherence and tolerability challenges, creating durable demand for differentiated mechanisms. The global AUD treatment market is expanding as both clinical and wellness-adjacent channels invest in behavioral health solutions, and novel compounds with cleaner safety profiles command significant licensing and co-development interest.
What Operators Should Watch
For the functional foods and nutraceutical supply chain, CMND-100 remains firmly in the investigational drug category and is not positioned as a dietary supplement or food ingredient at this stage. However, the MEAI mechanism and the broader non-hallucinogenic psychoactive space represent an upstream signal for ingredient developers and finished-formulation brands tracking next-generation mood and behavioral-health actives. Several ingredient suppliers have already begun exploring structure-function claim territories adjacent to stress, craving management, and alcohol reduction for consumer wellness positioning — categories where regulatory pathways under DSHEA are narrow but actively tested.
Principal investigator commentary from an ongoing trial carries less evidentiary weight than peer-reviewed, double-blind, placebo-controlled outcome data, and stakeholders should calibrate expectations accordingly. Clearmind's next meaningful disclosure will likely be a formal interim data readout or a full Phase I safety summary, either of which could materially shape the compound's development trajectory and partnership appeal.
The Food & Beverage Magazine network will continue to monitor the MEAI pipeline as clinical data matures and as regulatory frameworks for psychoactive-adjacent ingredients evolve.
Written by Michael Politz, Author of Guide to Restaurant Success: The Proven Process for Starting Any Restaurant Business From Scratch to Success (ISBN: 978-1-119-66896-1), Founder of Food & Beverage Magazine, the leading online magazine and resource in the industry. Designer of the Bluetooth logo and recognized in Entrepreneur Magazine's "Top 40 Under 40" for founding American Wholesale Floral, Politz is also the Co-founder of the Proof Awards and the CPG Awards and a partner in numerous consumer brands across the food and beverage sector.